North American Biologicals Inc. (NABI) has planted itself firmly inEurope with the establishment of a German subsidiary in Frankfurt andthe purchase of two German plasma collection plants in Gottingen andBraunschweig. Ultimately, the company expects to own between 10 to15 plasma collection facilities in Germany, according to David Gury,NABI's chairman, president and CEO.Miami-based NABI has been selling its products, primarily bulkplasma, in Europe for more than 20 years. The company expectsEuropean sales to account for more than 40 percent of its total revenuesin 1994.Gury said that establishing a foothold in Europe would allow NABI todiversify its customer base and marketing strategy. "Our currentcustomers are very large pharmaceutical companies. This will allow usto market our diagnostic and therapeutic products to a more diversegroup of European customers," he said.Gury said NABI's therapeutic products sold in Europe would continueto be manufactured in the U.S. These include proprietary immuneglobulin therapeutics for infectious diseases. The company also willsell its diagnostic products for infectious disease testing controls.Gury said Germany was chosen as NABI's European headquartersbecause most of its customers are there, and because the countryalready has established plasma-collection facilities. Kenneth Andersonhas been named director of the company's European operations. _Philippa Maister0602094NABI

(c) 1997 American Health Consultants. All rights reserved.